Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 14847 total
Cullinan Therapeutics heads into its November 6 earnings event with a stark gap between a stubbornly bearish lending market and a Street that has spent the past several weeks nudging targets higher. The positioning…
Palantir Technologies enters the week with a fresh Goldman Sachs upgrade landing just as the stock pushes to $194.12, answering last week's question about whether the resilience was real. Goldman analyst Gabriela…
Mission Produce heads into the final stretch of 2026 with two stories pulling in opposite directions: short sellers are quietly paring back positions while the company's dominant activist shareholder keeps…
XPeng is holding near the lows that followed JP Morgan's late-September downgrade, with the stock at $9.58, and the story this week is one of tentative stabilisation against a backdrop that still looks structurally…
VTRS heads into November earnings with an unusually constructive analyst backdrop, a modest short position, and a retail attention spike that stands out against an otherwise quiet positioning story. The Street's…
NetEase (9999) heads into November earnings with short interest creeping higher on the week, borrowing costs ticking up, and the stock trading below analyst targets, a setup where the bears are re-engaging but the…
COMPASS Pathways heads into its November 5 earnings date with short sellers quietly adding pressure and the stock nursing a 12% loss over the past month, even as the COMP360 regulatory story remains intact. Short…
Chord Energy enters the week before its November 4 earnings with a cluster of insider sales on the tape, even as sell-side analysts have spent the past fortnight raising targets and short sellers tentatively rebuild…
IMVT heads into its November 6 earnings with short interest building steadily, the stock down 18% over the past month, and a wide gap between where bulls think it can go and where it trades today. The short side tells…
Phathom Pharmaceuticals heads into its October 29 earnings report down 28% over the past month, with short sellers retreating slightly but the stock's own history giving bears plenty to work with. The most telling…
Datadog enters its November 6 earnings window with a curious split: the stock has rallied 27% over the past month to $271.34, yet short sellers have quietly been adding to their positions and options traders remain…
DT heads into its November 5 earnings with analysts raising targets, short sellers rebuilding positions, and options traders taking out more downside cover than they have in months. The Street has been notably…
PHR heads into the final stretch of 2026 with an activist on the register, a stock sitting at just $10.50, and a Street that can't agree on whether the worst is behind it. The most consequential ownership story is the…
The RealReal heads into its November 3 earnings with short interest stubbornly elevated, insiders having sold in August, and options traders tilting more cautious than they were just weeks ago. Short sellers are not…
CrowdStrike enters the new week with short sellers at their most committed level in months, a BMO analyst raising his target by $60 in a single move, and a CEO selling into every session, all while the stock gave back…
Elanco Animal Health heads into its November 6 earnings with a notable insider buying cluster, modest short rebuilding, and a Street that remains constructively positioned well above the current price. The most…
Champion Homes has shed 5.4% this week to close at $81.03, giving back gains that followed its last earnings beat, with the October 27 print now just 19 days away and the stock sitting 14% below where several analysts…
Scholar Rock Holding Corporation enters the final stretch before its November 11 earnings with a deteriorating price trend, a short position that has grown steadily for six weeks, and a Street that remains broadly…
AIQ, the Global X Artificial Intelligence & Technology ETF, heads into the week with a notable split in its lending market: shares short rose 27% over the past week, yet borrow conditions remain relatively low-cost and…
Ginkgo Bioworks faces its sharpest test of its recent rally. The stock fell 7.6% on Wednesday to $11.47, cutting its one-week loss to 10.6%, even as it retains a 65% gain over the past month. Short sellers have been…
